# Chase Therapeutics Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chase-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Washington, US
- Website: www.chasetherapeutics.com
- Total disclosed funding: $20M
- Latest round: Series B (Oct 20, 2021)
- Investors on record: 4

## About

Chase Therapeutics Corporation is focused on developing novel pharmaceuticals for neuropsychiatric conditions, particularly targeting Parkinson’s disease and major depressive disorder through innovative therapeutic mechanisms.Chase Therapeutics Corporation, founded in 2017 and headquartered in Washington, US, specializes in the development of treatments for neuropsychiatric diseases. The company has undergone strategic pivots to enhance its focus on these areas. The organization was co-founded by Kathleen Clarence-Smith and is currently led by CEO Thomas Chase. Since its inception, Chase has raised USD 20.00 mn in funding through three deals, with the latest being a Series B round in October 2021, which was led by Chinalink Asia Holdings Limited and included investors such as Brain Trust Accelerator Fund and Revolution Ventures.Chase Therapeutics is engaged in the development of innovative pharmaceutical products aimed at addressing neuropsychiatric diseases, particularly focusing on Parkinson’s disease and major depressive disorder. The company's lead products, CTC-413 and CTC-501, provide symptomatic relief and neuroprotection for patients suffering from these conditions and are currently progressing through Phase 2 clinical evaluations. The target customer base includes healthcare providers and institutions specializing in neurology and psychiatry, as well as patients diagnosed with these disorders, primarily in the US and Europe.Chase Therapeutics generates revenue through partnerships with healthcare institutions and clinical trial collaborations, which are essential to its drug development strategy. The company engages in agreements with clinical research organizations, hospitals, and specialty pharmacies, facilitating distribution of its products upon market release. Funding is also expected from licensing agreements and potential future sales of CTC-413 and CTC-501, following regulatory approval, with transactions often involving milestone payments linked to clinical trial progress and market release.Chase Therapeutics plans to use the USD 20.00 mn raised in Series B funding, as of October 2021, to support pivotal Phase 3 trials for CTC-501 targeting Major Depressive Disorder (MDD) and CTC-413 for Parkinson’s Disease (PD). The company is also focused on completing the development and validation of a diagnostic product for Parkinson’s Disease. Future expansions into new markets are anticipated, particularly in Europe, where there is a significant demand for advanced neuropsychiatric treatments.

## Funding rounds

- Series B, Oct 20, 2021, $20M — Revolution Ventures, Brain Trust Accelerator Fund, Makana Ventures, Chinalink Asia Holdings Limited

## Investors

- Revolution Ventures (https://capitalatlas.ai/funds/revolution-ventures) — Series B
- Brain Trust Accelerator Fund (https://capitalatlas.ai/funds/brain-trust-accelerator-fund) — Series B
- Makana Ventures (https://capitalatlas.ai/funds/makana-ventures) — Series B
- Chinalink Asia Holdings Limited — Series B